The Urology Department is responsible for the medical and surgical treatment of pathologies associated with the male and female urinary tract and the male genitalia.
Its activities are essentially diagnosis and treatment and the monitoring of cancerous and non-cancerous conditions affecting the prostate, kidneys, bladder and male genitalia.
As our work is principally oncological in nature, we operate a strongly multidisciplinary approach to the treatment of all cancerous conditions associated with the genitourinary system.
Our team therefore works in close and constant collaboration with the Institut Bordet’s medical oncologists, radiotherapists, radiologists, nuclear medicine specialists and anatomopathologists.
The Institut Bordet Urology Department treats :
- prostate conditions:
- diagnosis of all prostate diseases
- treatment of benign prostate hypertrophia
- refinement (diagnosis) of prostate cancers via different examinations including biopsies conducted on an out-patient basis and under local anaesthesia
- hormone treatments
- surgical treatments mainly via robotic surgery
- focused ultrasound prostate treatment.
- Bladder conditions:
- treatment of incontinence problems (surgery, rehabilitation, urodynamic testing, etc)
- treatment of common bladder infections (for example, cystitis)
- diagnosis and treatment of bladder polyps (via fluorescent light)
- diagnosis and surgical treatment of malignant bladder tumours (cancers) with bladder reconstruction in cases of total organ ablation.
- Kidney and ureteral conditions:
- diagnosis and treatment of infectious diseases of the kidney (pyelonephritis, for example), renal calculi (kidney stones), etc.
- diagnosis and treatment of benign kidney tumours (cysts, for example)
- diagnosis and treatment of malignant tumours (cancers) of the kidney
- robotic surgery.
- Conditions affecting the male genitalia:
- diagnosis and treatment of cancerous and non-cancerous tumours of the penis and testicles
- laser treatment and sentinel node technique.
The Institut Bordet Urology Department is at the leading edge of fusion imaging, targeting and focused prostate cancer treatments (MRI – ultrasound – high frequency ultrasound).
Thanks to advances in medical imaging, in particular magnetic resonance imaging of the prostate, it is now possible to define suspect areas within the prostate. The Institut Bordet is the first centre to offer fusion imaging software. This software makes it possible to achieve very high precision guidance of the biopsies needed to characterise cancer. This fusion imaging is then exported in order to carry out focused treatment of the affected zones using high-energy ultrasound, thus allowing non-invasive, transrectal treatment of prostate cancer.
Head of Department
Dr A. Peltier
Dr R. Diamand
Dr F. Aoun
Dr A. Mattlet
Dr R. Abou Zahr
Administrative Secretary and Secretary of the Head of Service
Tel : 02/541.31.74
Secretary (appointments, reception)
Tel : 02/541.34.48
Indications for and complications of pelvic lymph node dissection in prostate cancer: accuracy of available nomograms for the prediction of lymph node invasion.
Authors : Oderda M, Diamand R, Albisinni S, Calleris G, Carbone A, Falcone M, Fiard G, Gandaglia G, Marquis A, Marra G, Parola C, Pastore A, Peltier A, Ploussard G, Roumeguère T, Sanchez-Salas R, Simone G, Smelzo S, Witt JH, Gontero P
Year : 2021
Journal : BJU Int
Volume : 127
Pages : 318-325
External Validation of a Multiparametric Magnetic Resonance Imaging-based Nomogram for the Prediction of Extracapsular Extension and Seminal Vesicle Invasion in Prostate Cancer Patients Undergoing Radical Prostatectomy.
Authors : Diamand R, Ploussard G, Roumiguié M, Oderda M, Benamran D, Fiard G, Quackels T, Assenmacher G, Simone G, van Damme J, Malavaud B, Iselin C, Descotes JL, Roche JB, Peltier A, Roumeguère T, Albisinni S
Year : 2021
Journal : Eur Urol
Volume : 79
Pages : 180-185
Stratifying patients with intermediate-risk prostate cancer: Validation of a new model based on MRI parameters and targeted biopsy and comparison with NCCN and AUA subclassifications.
Authors : Diamand R, Ploussard G, Roumiguié M, Malavaud B, Oderda M, Gontero P, Fourcade A, Fournier G, Benamran D, Iselin C, Fiard G, Descotes JL, Peltier A, Simone G, Roche JB, Roumeguère T, Albisinni S
Year : 2021
Journal : Urol Oncol
Volume : 39
Pages : 296.e1-296.e9
Does antibiotic use explain the discrepancy of urolithiasis prevalence between countries?
Authors : Karam A, Mjaess G, Aoun F, Albisinni S, Vafa H, Roumeguere T
Year : 2021
Journal : Urolithiasis
Volume : 49
Pages : 181-182
Pudendal nerve release for lower urinary tract symptoms in young males.
Authors : Aoun F, Mjaess G, Akl B, Nassar D, Kallas Chemaly A, Haydar A, Raad R, Absil F, Nemr E, Bollens R
Year : 2021
Journal : Low Urin Tract Symptoms
Volume : 13
Pages : 286-290